MA52212A - Anticorps multivalent - Google Patents

Anticorps multivalent

Info

Publication number
MA52212A
MA52212A MA052212A MA52212A MA52212A MA 52212 A MA52212 A MA 52212A MA 052212 A MA052212 A MA 052212A MA 52212 A MA52212 A MA 52212A MA 52212 A MA52212 A MA 52212A
Authority
MA
Morocco
Prior art keywords
multivalent antibody
multivalent
antibody
Prior art date
Application number
MA052212A
Other languages
English (en)
Inventor
Kruif Cornelis Adriaan De
Linda Johanna Aleida Hendriks
Ton Logtenberg
Loo Pieter Fokko Van
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MA52212A publication Critical patent/MA52212A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA052212A 2018-03-30 2019-03-29 Anticorps multivalent MA52212A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862650467P 2018-03-30 2018-03-30

Publications (1)

Publication Number Publication Date
MA52212A true MA52212A (fr) 2021-02-17

Family

ID=66349617

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052212A MA52212A (fr) 2018-03-30 2019-03-29 Anticorps multivalent

Country Status (17)

Country Link
US (1) US11952424B2 (fr)
EP (1) EP3774885A2 (fr)
JP (1) JP2021519610A (fr)
KR (1) KR20200139189A (fr)
CN (1) CN111936514A (fr)
AR (1) AR115320A1 (fr)
AU (2) AU2019243665B2 (fr)
BR (1) BR112020019795A2 (fr)
CA (1) CA3094318A1 (fr)
EA (1) EA202091871A1 (fr)
IL (1) IL277672A (fr)
MA (1) MA52212A (fr)
MX (1) MX2020010267A (fr)
PH (1) PH12020551504A1 (fr)
SG (1) SG11202009036YA (fr)
TW (1) TW202003569A (fr)
WO (1) WO2019190327A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR115320A1 (es) 2018-03-30 2020-12-23 Merus Nv Anticuerpo multivalente
CA3124768A1 (fr) 2018-12-31 2020-07-09 Merus N.V. Domaines de liaison mixtes
CN113439089A (zh) 2018-12-31 2021-09-24 美勒斯公司 截短的多价多元体
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
TW202108613A (zh) 2019-05-09 2021-03-01 荷蘭商美勒斯公司 用於多聚化蛋白質及其分離的變異區域
CN115038497A (zh) 2019-12-24 2022-09-09 美勒斯公司 TGF-β-RII结合蛋白质
AU2021214622A1 (en) * 2020-01-29 2022-07-21 Merus N.V. Means and method for modulating immune cell engaging effects.
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
MX2022014208A (es) 2020-05-21 2022-12-07 Merus Nv Metodos y medios para la produccion de moleculas tipo ig.
IL315265A (en) * 2022-03-03 2024-10-01 Pfizer Inc Multiple antibodies and their uses
WO2023201309A1 (fr) * 2022-04-13 2023-10-19 Xencor, Inc. Anticorps se liant à pd-1, à pd-l2 et/ou à cd28
WO2024144396A1 (fr) 2022-12-27 2024-07-04 Merus N.V. Procédé de production de protéines bispécifiques
US20240262911A1 (en) * 2022-12-30 2024-08-08 Merus N.V. Promiscuous cd3 binding molecules
CN116813744B (zh) * 2023-02-23 2024-02-23 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
EP1272647B1 (fr) * 2000-04-11 2014-11-12 Genentech, Inc. Anticorps multivalents et leurs utilisations
WO2002002781A1 (fr) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Proteines de fusion heterodimeres
AU2001283496A1 (en) * 2000-07-25 2002-02-05 Immunomedics, Inc. Multivalent target binding protein
CA2965865C (fr) 2002-07-18 2021-10-19 Merus N.V. Production par recombinaison de melanges d'anticorps
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2906344T3 (es) 2008-06-27 2022-04-18 Merus Nv Animal murino transgénico productor de anticuerpos
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
MX2011012299A (es) 2009-05-20 2012-03-29 Novimmune Sa Librerias de polipeptidos sinteticos y metodos para generar variantes de polipeptido naturalmente diversificadas.
DK3279215T3 (da) 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1
EP2513312B1 (fr) 2009-12-17 2015-03-18 NovImmune SA Bibliothèques de polypeptides synthétiques et procédés de production de variants polypeptidiques naturellement diversifiés
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
JP2015527869A (ja) * 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムＦｃ二重特異性抗体
SI2785375T1 (sl) 2011-11-28 2020-11-30 Merck Patent Gmbh Protitelesa proti PD-L1 in uporabe le-teh
AU2013249985B2 (en) 2012-04-20 2017-11-23 Merus N.V. Methods and means for the production of Ig-like molecules
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN115093480A (zh) 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
WO2014022540A1 (fr) 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Protéines multivalentes de liaison à un antigène
ES2692951T3 (es) 2012-09-27 2018-12-05 Merus N.V. Anticuerpos IgG biespecíficos como acopladores de células T
WO2014122143A1 (fr) 2013-02-05 2014-08-14 Engmab Ag Procédé de sélection d'anticorps anti-bcma
WO2014131711A1 (fr) 2013-02-26 2014-09-04 Roche Glycart Ag Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
EP2789630A1 (fr) 2013-04-09 2014-10-15 EngMab AG Anticorps bispécifiques contre le CD3e et ROR1
RU2016129959A (ru) * 2013-12-30 2018-02-02 Эпимаб Биотерепьютикс Инк. Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
KR20240042540A (ko) 2014-02-28 2024-04-02 메뤼스 엔.페. ErbB-2와 ErbB-3에 결합하는 항체
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
TWI742423B (zh) 2014-05-29 2021-10-11 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
EP2982692A1 (fr) 2014-08-04 2016-02-10 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
CA2963696A1 (fr) 2014-10-09 2016-04-14 Engmab Ag Anticorps bispecifiques diriges contre cd3epsilon et ror1 a utiliser dans le traitement du cancer des ovaires
US11952421B2 (en) 2014-10-09 2024-04-09 Bristol-Myers Squibb Company Bispecific antibodies against CD3EPSILON and ROR1
EP3023437A1 (fr) 2014-11-20 2016-05-25 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
WO2016105450A2 (fr) * 2014-12-22 2016-06-30 Xencor, Inc. Anticorps trispécifiques
MY194225A (en) 2015-03-13 2022-11-22 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
CA2991880A1 (fr) * 2015-07-10 2017-01-19 Merus N.V. Anticorps se liant a un cd3 humain
HUE048939T2 (hu) 2015-08-03 2020-09-28 Engmab Sarl Human B sejt érési antigén elleni monoklonális antitestek (BCMA)
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
SI3365373T1 (sl) * 2015-10-23 2021-08-31 Merus N.V. Vezne molekule, ki zaviranjo rast raka
RU2764201C2 (ru) 2016-03-25 2022-01-14 Биомюнё Фармасьютикалз Связывающиеся с cd38 и pd-l1 молекулы
CN109415436A (zh) * 2016-04-27 2019-03-01 辉瑞公司 抗il-33抗体及其组合物、方法及用途
ES2952951T3 (es) 2016-04-28 2023-11-07 Biomunex Pharmaceuticals Anticuerpos biespecíficos dirigidos a EGFR y HER2
CN109983033B (zh) 2016-09-23 2023-10-31 美勒斯公司 调节细胞表达的生物活性的结合分子
AU2017345454A1 (en) 2016-10-19 2019-05-30 Invenra Inc. Antibody constructs
KR102687833B1 (ko) 2016-11-02 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도
CA3058341A1 (fr) * 2017-03-31 2018-10-04 Merus N.V. Anticorps pour le traitement de tumeurs positives erbb-2/erbb-3
MX2019011660A (es) * 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
WO2019009727A1 (fr) * 2017-07-06 2019-01-10 Merus N.V. Anticorps bispécifiques anti-pd1 anti-tim3
IL271833B2 (en) * 2017-07-06 2024-09-01 Merus Nv Antibodies that regulate biological activity expressed by a cell
EP3649154A1 (fr) * 2017-07-06 2020-05-13 Merus N.V. Molécules de liaison permettant de moduler l'activité biologique exprimée par une cellule
KR20200042485A (ko) * 2017-08-09 2020-04-23 메뤼스 엔.페. EGFR 및 cMET에 결합하는 항체
EP3717008A1 (fr) * 2017-12-01 2020-10-07 Merus N.V. Utilisation d'un anticorps bispécifique et d'il-15 en polythérapie
AR115320A1 (es) 2018-03-30 2020-12-23 Merus Nv Anticuerpo multivalente
CA3124768A1 (fr) * 2018-12-31 2020-07-09 Merus N.V. Domaines de liaison mixtes
TW202108613A (zh) * 2019-05-09 2021-03-01 荷蘭商美勒斯公司 用於多聚化蛋白質及其分離的變異區域
IL293215A (en) * 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
AU2021214622A1 (en) * 2020-01-29 2022-07-21 Merus N.V. Means and method for modulating immune cell engaging effects.

Also Published As

Publication number Publication date
IL277672A (en) 2020-11-30
BR112020019795A2 (pt) 2021-01-05
AU2019243665A1 (en) 2020-10-08
CN111936514A (zh) 2020-11-13
EA202091871A1 (ru) 2021-06-22
TW202003569A (zh) 2020-01-16
AR115320A1 (es) 2020-12-23
CA3094318A1 (fr) 2019-10-03
AU2019243665B2 (en) 2023-06-01
JP2021519610A (ja) 2021-08-12
US20190352401A1 (en) 2019-11-21
KR20200139189A (ko) 2020-12-11
MX2020010267A (es) 2020-11-06
WO2019190327A8 (fr) 2021-06-17
EP3774885A2 (fr) 2021-02-17
PH12020551504A1 (en) 2021-09-13
WO2019190327A2 (fr) 2019-10-03
WO2019190327A3 (fr) 2019-11-14
US11952424B2 (en) 2024-04-09
SG11202009036YA (en) 2020-10-29
AU2023222983A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
MA52212A (fr) Anticorps multivalent
MA53434A (fr) Anticorps anti-tigit
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA52884A (fr) Anticorps anti-il-11
MA47268A (fr) Anticorps anti-gpc3
MA52742A (fr) Anticorps bispécifiques dll3-cd3
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
ES2981193T3 (es) Anticuerpos antisirpalpha
MA51428A (fr) Récepteur d'antigène chimérique multivalent
MA52152A (fr) Anticorps
MA46272A (fr) Anticorps anti-cd27
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA49749A (fr) Anticorps anti-cd137
DK3544636T3 (da) Pyrrolobenzodiazepin-antistof-konjugater
MA53905A (fr) Anticorps stabilisant trem2
MA50352A (fr) Anticorps multispécifiques
DK3504241T3 (da) Anti-cd3-antistofformuleringer
MA52366A (fr) Anticorps anti-tl1a optimisés
DK3606961T3 (da) Garp-tgf-beta-antistoffer
MA44236A (fr) Anticorps anti-tgfbêta 2
MA51134A (fr) Anticorps anti-alpha-synucléine
DK3642227T3 (da) Hundeantistofbiblioteker
MA49250A (fr) Nouveaux anticorps anti-cd3
MA42843A (fr) Anticorps anti-cd115